Literature DB >> 2408645

Inhibition of histamine release from dispersed human lung and tonsillar mast cells by nicardipine and nifedipine.

Y Y Kim, S T Holgate, M K Church.   

Abstract

Calcium entry blocking drugs attenuate antigen-induced bronchoconstriction in asthma which is mast cell mediated. We have investigated the effects of two calcium uptake blockers, nicardipine and nifedipine on histamine secretion from human mast cells dispersed from lung and tonsillar tissue. Mast cells were activated for secretion with anti-human IgE or calcium ionophore, A23187. Nicardipine and nifedipine caused a concentration-related inhibition of IgE-dependent histamine release from both lung (IC30 10 microM and 4.4 microM) and tonsillar (IC30 21 microM and 47 microM) mast cells. Nicardipine and nifedipine also inhibited mast cell histamine release induced by A23187 with IC30 values of 14 microM and 67 microM for lung and 15 microM and 30 microM for tonsillar mast cells. In the absence of drugs, increasing the extracellular calcium concentrations from 0.2 to 5 mM caused a concentration related increase in IgE-dependent histamine release from tonsillar mast cells. Both nicardipine and nifedipine (50 microM) displaced the concentration-effect curve to the right. Nicardipine (0.01-100 microM) caused a concentration related inhibition of rat kidney histamine methyltransferase activity used in the radioenzymatic assay of histamine (ki of 7.5-12 microM) whereas nifedipine was only a weak inhibitor. Nicardipine also interfered with the spectrofluorimetric assay after exposure to ultraviolet light. These observations demonstrate that nicardipine and nifedipine inhibit IgE-dependent and ionophore stimulated mediator secretion from human mast cells. The lack of stimulus-related specificity and the high drug concentrations required suggest that classical calcium channel blockade is not responsible for inhibition of mast cell mediator release. Furthermore, we suggest that inhibition of mast cell mediator release is unlikely to be the mechanism by which these drugs alleviate asthma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2408645      PMCID: PMC1463845          DOI: 10.1111/j.1365-2125.1985.tb02690.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  33 in total

Review 1.  Mechanisms of action of transmitters and other substances on smooth muscle.

Authors:  T B Bolton
Journal:  Physiol Rev       Date:  1979-07       Impact factor: 37.312

2.  New inhibitors of histamine-N-methyltransferase.

Authors:  M A Beaven; R E Shaff
Journal:  Biochem Pharmacol       Date:  1979       Impact factor: 5.858

3.  Verapamil inhibits mediator release from human lung in vitro.

Authors:  V Y Lee; J M Hughes; J P Seale; D M Temple
Journal:  Thorax       Date:  1983-05       Impact factor: 9.139

4.  Calcium-channel blockers and asthma.

Authors:  P J Barnes
Journal:  Thorax       Date:  1983-07       Impact factor: 9.139

Review 5.  Antiasthmatic drug therapy and calcium ions: review of pathogenesis and role of calcium.

Authors:  E Middleton
Journal:  J Pharm Sci       Date:  1980-02       Impact factor: 3.534

6.  Brain histamine N-methyltransferase purification, mechanism of action, and inhibition by drugs.

Authors:  A Thithapandha; V H Cohn
Journal:  Biochem Pharmacol       Date:  1978-02-01       Impact factor: 5.858

7.  Inhibitory effect of nifedipine and cromolyn sodium on skin reactions and 45Ca uptake and histamine release in rat mast cells induced by various stimulating agents.

Authors:  Y Tanizaki; K Akagi; K N Lee; R G Townley
Journal:  Int Arch Allergy Appl Immunol       Date:  1983

8.  The bronchial response to cold air challenge: evidence for different mechanisms in normal and asthmatic subjects.

Authors:  R W Heaton; A F Henderson; B J Gray; J F Costello
Journal:  Thorax       Date:  1983-07       Impact factor: 9.139

9.  Effects of nitrendipine (BAY e 5009), nifedipine, verapamil, phentolamine, papaverine, and minoxidil on contractions of isolated rabbit aortic smooth muscle.

Authors:  R Towart
Journal:  J Cardiovasc Pharmacol       Date:  1982 Nov-Dec       Impact factor: 3.105

10.  Nifedipine in bronchial asthma.

Authors:  D Patakas; E Vlachoianni; V Tsara; G Louridas; P Argiropoulou
Journal:  J Allergy Clin Immunol       Date:  1983-09       Impact factor: 10.793

View more
  7 in total

1.  Contribution to enrichment of korean academy of asthma allergy clinical immunology: homage to professor you-young kim, the pioneer exploring allergology in Korea.

Authors:  Sang Heon Cho
Journal:  Allergy Asthma Immunol Res       Date:  2010-06-04       Impact factor: 5.764

2.  A brief history of asthma and its mechanisms to modern concepts of disease pathogenesis.

Authors:  Stephen T Holgate
Journal:  Allergy Asthma Immunol Res       Date:  2010-05-06       Impact factor: 5.764

3.  Past, present, and future of allergy in Korea.

Authors:  You-Young Kim
Journal:  Allergy Asthma Immunol Res       Date:  2010-06-15       Impact factor: 5.764

4.  On the isolation of mast cells from human adenoids and tonsils.

Authors:  N Grosman; C Hjort-Sørensen; S M Jensen
Journal:  Agents Actions       Date:  1987-04

5.  Inhibition of exercise-induced asthma by nifedipine: a dose-response study.

Authors:  P Rafferty; J G Varley; J S Edwards; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

Review 6.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

7.  Progress and Prospect: A Bibliometric Analysis of Research Papers by Korean Allergists Over Recent Five Years (2009-2013).

Authors:  Woo Jung Song; Hye Mi Jee; Dong In Suh; Hyeon Jong Yang; Jong Seo Yoon; Jinho Yu; Sang Heon Kim; Young Min Ye; Tae Bum Kim; Seung Youp Shin; Kapsok Li; Cheol Woo Kim
Journal:  Allergy Asthma Immunol Res       Date:  2015-04-15       Impact factor: 5.764

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.